Company profile
MINERALYS THERAPEUTICS, INC.
NASDAQ:MLYSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LORUNDROSTAT HYDROBROMIDE | phase2 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05769608 | phase2 | completed | 2023-03-13 | 2025-01-15 | Mineralys Therapeutics Inc. | A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
| NCT06785454 | phase2 | completed | 2025-02-28 | 2025-12-17 | Mineralys Therapeutics Inc. | A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension |
| NCT06150924 | phase2 | completed | 2023-12-14 | 2025-02-27 | Mineralys Therapeutics Inc. | Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria |
| NCT06153693 | phase3 | completed | 2023-11-22 | 2024-12-10 | Mineralys Therapeutics Inc. | Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
| NCT05968430 | phase3 | active_not_recruiting | 2023-07-14 | 2025-12-30 | Mineralys Therapeutics Inc. | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension |
FDA applications (0)
No records yet.